10:38 PM
 | 
May 11, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Braeburn’s BB0817 risperidone implant meets Phase II/III PK endpoint

Braeburn Pharmaceuticals Inc. (Princeton, N.J.) reported data from a Phase II/III trial in more than 50 stabilized schizophrenic patients showing that BB0817 met the primary endpoint of achieving comparable plasma levels of 9-hydroxy-risperidone -- the active metabolite...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >